This study attempts to address two of the current blockers to tumor immunotherapy for patients; one is to trigger more actively and efficiently specific anti-tumor immunity that involves polymorphic antigen presenting molecules such as MHC, and the heterogenically expressing TAAs in the cancer patient population. This evidence concerns the gene HLA-C and cancer.